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Background: We report a clinically diagnosed acute lymphoblastic leukemia (ALL) with yet unreported secondary
chromosomal aberrations.
Results: A complete cytogenetic and molecular cytogenetic analysis, using GTG banding, fluorescence in situ
hybridization (FISH) and array-proven multicolor banding (aMCB), for a female patient with clinically diagnosed
ALL and immunophenotypically confirmed pre-B ALL (FAB classifications), revealed the presence of a complex
structural rearrangement, der (2) (20qter- > 20q13.33::2q21- > 2p14::2q21 > 2qter) along with t (9;22) (q34;q11),
t (12;14) (q12;p12) and a monosomy of chromosome 7.
Conclusions: Molecular cytogenetic studies are suited best for identification and characterization of chromosomal
rearrangements in acute leukemia. Single case reports as well as large scale studies are necessary to provide further
insights in karyotypic changes taking place in human malignancies.
Keywords: Acute lymphoblastic leukemia, Secondary chromosomal abnormalities, Philadelphia chromosome,
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Acute lymphoblastic leukemia (ALL) is a heterogeneous
disease characterized by multiple subtypes [1]. To date,
several structural and numerical chromosomal abnor-
malities have been characterized in ALL and according
to the WHO classification the following, seven genetic
subtypes are defined for B lymphoblastic leukemia, t
(9:22) (q34;q11.2), 11q23 traslocations, t (12;21) (p13;q22),
t (1;19) (q23;p13.3), t (5;14) (q31;q32), hyperdiploidy and
hypodiploidy [2]. Among the genetic subtypes, Philadel-
phia (Ph) chromosome, which results from a reciprocal
translocation between Abelson (ABL1) from chromosome
9 and breakpoint cluster region (BCR) from chromosome
22, is the most frequent cytogenetic aberration which is
found in ~ 25% of adult ALL cases, and in more than 50%
of patients, aged 50 years or more [3,4]. The presence of* Correspondence: ascientific@aec.org.sy
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ALL and represents the most significant adverse prognos-
tic marker that influences the disease outcome [5]. Ph
positive (Ph+) ALL is a more aggressive disease than
chronic myeloid leukemia (CML), indicating that other
factors than BCR-ABL1 are involved in its development
and progression [5,6]. Ph + precursor-B-ALL is highly ag-
gressive, frequently resistant to chemotherapy and with a
short survival time [6,7]. Here, we are presenting a Ph +
pre-B-ALL case with yet unreported translocation events
involving six different chromosomes and a monosomy 7.
These chromosomal rearrangements appeared after un-
successful chemotherapy treatment.Case presentation
A 31-year-old woman was diagnosed as suffering from
ALL in September 2011. Anemia, thrombocytopenia, diar-
rhea, fatigue and weight loss were the indicative symp-
toms. She was treated as follows: after the first GM-ALL
protocol (phase I and II) failed, Flag-IDA protocol wastral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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protocol (phase I and II) was applied and after being un-
successful hyper-CVAD was applied. At this point the first
cytogenetics and hematology were determined. The
patient's hematologic parameters were white blood cells
(WBC) at 123×109/l, consisting of 12% neutrophils, 75%
lymphocytes, 11% monocytes and 1% basophiles. Red
blood cell (RBC) count was 3.26×106/mm3, hemoglobin
level 9.7 g/dl and the platelet count 34×109/l. Serum lac-
tate dehydrogenase (LDH) value was 2,712 U/l (normal
value up to 480 U/l), serum alkaline phosphates value 208
U/l (normal value up to 128 U/l), serum alanine amino-
transferase 198 U/l (normal value up to 40 U/l) and serum
aspartate aminotransferase value 139 U/l (normal value
up to 40 U/l). The patient was treated further according
to standard ALL chemotherapy protocols for fourteen
months, however, without clinical success of chemother-
apy. Unfortunately she died under the treatment.
Results
A sample of a female patient diagnosed as pre B-ALL,
according to FAB classifications, was received after the
completion of three different protocols of chemotherapy.
The conventional cytogenetics analysis by GTG banding
revealed the karyotype as 45, XX, -7, der (2) t (2;20)
(?;?), t (9;22) (q34;q11), t (12;14) (q?;p?) [12] / 46, XX, t
(12;14) (q?;p?) [10] (Figure 1). The dual color FISH using
the probe specific for BCR and ABL and WCP probes
specific for chromosomes 2, 7, 12, 14 and 20 confirmed
the presence of BCR/ABL fusion on der (22) (data not
shown), and the presence of the other rearrangements.
To further characterize the breakpoints, aMCB wasFigure 1 GTG-banding revealed a 45, XX-7, der (2) t (2;20), t (9;22), t (performed, as previously reported [8] (Figure 2) and the
final karyotype was redefined as: 45, XX,-7, der (2)
(20qter- > 20q13.33::2q21- > 2p14::2q21 > 2qter), t (9;22)
(q34;q11), t (12;14) (q12;p12) [12] / 46, XX, t (12;14)
(q12;p12) [10].
The abnormal cell population showed the following
immunophenotype, which was consistent with pre-B-
ALL (FAB classifications): CD45+, HLADr+, CD117+,
CD34+, CD19+, CD10+, CD38+ and expressed CD123
and CD11c (52%) heterogeneously. The abnormal cells
negatively reacted with antibodies to CD5, CD64 and
CD3.
Conclusions
We characterized a Ph + adult pre-B-ALL case with a
complex secondary chromosomal abnormality, a trans-
location and a monosomy 7. According to the literature,
not a single case of ALL showed a der (2) (20qter- >
20q13.33::2q21- > 2p14::2q21- > 2qter) plus a t (12;14)
(q12;p12) [9]. Moreover, a t (12;14) (q12;p12) was ob-
served only in two cases of mantle cell lymphoma [9]
and in a case of acute myeloid leukemia [10]. On the
other hand, the chromosomal bands, 2p14, 2q21, 12q12,
and 14p12 are listed in 5, 32, 20, and 4 cases, respect-
ively, in other rearrangements involving different chro-
mosomes than the ones which are involved in the
present case, in previously reported ALL cases [9]. In
addition, inv (2) with 2q21 as one of the breakpoints has
also been reported in 3 cases of ALL [9].
Till date, several chromosomal aberrations such as t
(9;22), t (4;11), t (1;9), and hyperdiploid or hypodiploid
karyotype have been associated with the prognostic12;14). All derivative chromosomes are shown with arrows.
Figure 2 Array-proven multicolor banding (aMCB) was applied to characterize the breakpoint locations. Each image shows the results of
MCB analysis using probe sets for chromosomes 2, 9, 12, 14, 20 and 22. The normal chromosomes are shown in the left side of each image and
the derivative chromosomes on the right. The MCB-probes unstained regions on the derivative chromosomes are shown in gray. Abbreviations:
# = chromosome; der = derivative chromosome; Ph = Philadelphia chromosome.
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BCR-ABL and t (4;11) (q21;q23)/MLL-AF4, an elevated
white blood cell count, age over 40 and non-responders/
slow responders to chemotherapy are commonly
regarded as high risk criteria in ALL [11]. Monosomy 7,
as a sole secondary abnormality, is also related with a
poor prognosis and shorter survival in adult ALL cases
[12,13]. In addition, deletions of 7p confer with an infer-
ior outcome in children with ALL, regardless of the
presence of other poor prognostic features, whereas de-
letions of 7q are not associated with an adverse outcome
[14]. The tendency for an adverse prognosis in patients
with secondary loss of chromosome 7 or 7p in Ph + ALL
may be the cumulative result of these events. Mullighan
et al. [15] recently described a deletion of IKZF1 gene
which encodes the transcription factor Ikaros, located
on 7p12 in 83.7% of Ph + ALL cases but not in chronic-
phase CML, suggesting that loss of Ikaros, a prototypical
member of the Krüppel-like zinc finger (ZnF) transcrip-
tion factor subfamily, which is required for normal
hematopoietic differentiation and proliferation, particu-
larly in lymphoid lineages, [16-18] is an important step
in the progression of Ph + ALL. Recently, two of seven
myeloproliferative neoplasms patients with loss of IKZF1
due to monosomy 7 have also been reported which sug-
gests that IKZF1 may represent an important tumor-
suppressor gene affected by monosomy 7 [19].The presence of the underlying BCR/ABL gene re-
arrangement in CD10 B-cell precursor ALL has been
reported previously [20] and it has already been demon-
strated that the occurrence of BCR-ABL positive ALL in
comparison to BCR-ABL negative disease represents a
subgroup with a worse prognosis within the CD10+ B-
lineage ALL [21].
In conclusion, the present case is a de novo case of
adult pre-B-ALL with yet unreported translocation




Chromosome analysis using GTG-banding was performed
according to standard procedures [22] 12 months after ig-
nition of the chemotherapeutic treatment. A minimum
of 20 metaphase cells derived from unstimulated bone
marrow culture were analyzed. Karyotypes were de-
scribed according to the International System for Hu-
man Cytogenetic Nomenclature [23].
Molecular cytogenetics
Fluorescence in situ hybridization (FISH) using LSI
BCR/ABL three-color dual-fusion translocation probe
(Abbott Molecular/Vysis, Des Plaines, IL, USA) was
applied according to manufacturer's instructions together
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mosomes 2, 7, 12, 14 and 20 (MetaSystems, Altlussheim,
Germany) [22]. FISH using the corresponding chromosome
specific array-proven multicolor banding (aMCB) probe
sets based on microdissection derived region-specific librar-
ies was performed as previously reported [8]. A minimum
of 20 metaphase spreads were analyzed, using a fluores-
cence microscope (AxioImager.Z1 mot, Carl Zeiss Ltd.,
Hertfordshir, UK) equipped with appropriate filter sets to
discriminate between a maximum of five fluorochromes
plus the counterstain DAPI (4',6- diamino-2-phenylindole).
Image capture and processing were performed using an
ISIS imaging system (MetaSystems).
Flow cytometric immunophenotype
Flow cytometric analysis was performed using a general
panel of fluorescent antibodies against the following an-
tigens typical for different cell lineages and cell types:
CD1a, CD2, CD3, CD4, CD5, CD8, CD10, CD11b,
CD11c, CD13, CD14, CD15, CD16, CD19, CD20, CD22,
CD23, CD32, CD33, CD34, CD38, CD41a, CD45, CD56,
CD57, CD64, CD103, CD117, CD123, CD138, CD209,
CD235a and CD243; In addition to antibodies to Kappa
and Lambda light Chains, IgD, sIgM, and HLADr. All
antibodies were purchased from BD Biosciences. Sam-
ples were analyzed on a BD FACSCalibur™ flow cyt-
ometer. Autofluorescence, viability, and isotype controls
were included. Flow cytometric data acquisition and
analysis were conducted by BD Cellquest™ Pro software.
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